ArticleEuropean urology2022
What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.
Erratum issuedOpen access · hybridAbstract readConsensus Statement
In one paragraph
Article in European urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 9 citations in OpenAlex.
- Change in Clinical Management of Localized Prostate Cancer Patients at a Tertiary Medical Center as a Result of SARS-CoV-2 (COVID-19).Prostate cancer · 2026Article
- Changes in the Use of Telephone Follow-ups among Patients with Urologic Malignancies in Japan.Annals of clinical epidemiology · 2025Article
- Impact of COVID-19 on hospital screening, diagnosis and treatment activities among prostate and colorectal cancer patients in Canada.International journal of health economics and management · 2023Article
- Communicating bad news to patients and families in African oncology settings.Psycho-oncology · 2023Article
- Article
- Article
Corrections and comments
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
86 authors at 20 institutions in 23 countries.
Fabio TurcoOncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland; Division of Medical Oncology, Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy. Electronic address: turcofabio9@gmail.com.
Andrew ArmstrongDuke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA.
Gerhardt AttardUniversity College London Cancer Institute, London, UK.
Tomasz M BeerKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Himisha BeltranDana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Anders BjartellDepartment of Urology, Skåne University Hospital, Malmö, Sweden.
Alberto BossiGenito Urinary Oncology, Prostate Brachytherapy Unit, Goustave Roussy, Paris, France.
Alberto BrigantiUnit of Urology/Division of Oncology, URI, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.
Rob G BristowDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; Christie NHS Trust and CRUK Manchester Institute and Cancer Centre, Manchester, UK.
Muhammad BulbulDivision of Urology, Department of Surgery, American University of Beirut Medical Center, Beirut, Lebanon.
Orazio CaffoDepartment of Medical Oncology, Santa Chiara Hospital, Trento, Italy.
Kim N ChiBC Cancer, Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada.
Caroline ClarkeResearch Department of Primary Care & Population Health, Royal Free Campus, University College London, Rowland Hill St, London, UK.
Noel ClarkeThe Christie and Salford Royal Hospitals, Manchester, UK.
Ian D DavisMonash University and Eastern Health, Victoria, Australia.
Johann de BonoThe Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Surrey, UK.
Ignacio DuranDepartment of Medical Oncology. Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Cantabria, Spain.
Ros EelesThe Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK.
Eleni EfstathiouHouston Methodist Cancer Center, Houston, TX, USA.
Jason EfstathiouDepartment of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA.
Christopher P EvansUniversity of California Davis School of Medicine, Sacramento, CA, USA.
Stefano FantiPoliclinico S. Orsola, Università di Bologna, Bologna, Italy.
Felix Y FengUniversity of California, San Francisco, San Francisco, CA, USA.
Karim FizaziInstitut Gustave Roussy, University of Paris Saclay, Villejuif, France.
Mark FrydenbergDepartment of Surgery, Monash University, Melbourne, Australia; Prostate Cancer Research Program, Department of Anatomy & Developmental Biology, Faculty of Nursing, Medicine & Health Sciences, Monash University, Melbourne, Australia.
Dan GeorgeDepartments of Medicine and Surgery, Duke Cancer Institute, Duke University, Durham, NC, USA.
Martin GleaveUrological Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada.
Susan HalabiDepartment of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA.
Daniel HeinrichDepartment of Oncology and Radiotherapy, Innlandet Hospital Trust, Gjøvik, Norway.
Celestia HiganoUniversity of British Columbia, Vancouver, British Columbia, Canada.
Michael S HofmanPeter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
Maha HussainRobert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.
Nicholas JamesThe Institute of Cancer Research, London, UK.
Rob JonesInstitute of Cancer Sciences, University of Glasgow, Glasgow, UK.
Ravindran KanesvaranDivision of Medical Oncology, National Cancer Centre, Singapore.
Raja B KhauliDepartment of Urology and the Naef K. Basile Cancer Institute (NKBCI), American University of Beirut Medical Center, Beirut, Lebanon.
Laurence KlotzDivision of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
Raya LeibowitzOncology institute, Shamir Medical Center, Zerifin, Israel; Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Christopher LogothetisDepartment of Genitourinary Medical Oncology, MD Anderson Cancer Centre, Houston, TX, USA; Department of Clinical Therapeutics, Alexandra Hospital, University of Athens, Athens, Greece; David H. Koch Centre, Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Centre, Houston, TX, USA.
Fernando MalufBeneficiência Portuguesa de São Paulo, São Paulo, SP, Brazil; Departamento de Oncologia, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
Robin MillmanPatient Advocate, UK.
Alicia K MorgansDana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Michael J MorrisMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Nicolas MottetUniversity Hospital Nord St Etienne, St Etienne, France.
Hind MrabtiNational Institute of Oncology, University hospital, Rabat, Morocco.
Declan G MurphyDivision of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.
Vedang MurthyTata Memorial Centre, Mumbai, India.
William K OhDivision of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY, USA.
Ngozi Ekeke OnyeanunamDepartment of Surgery, University of Port Harcourt Teaching Hospital, Alakahia, Port Harcourt, Nigeria.
Piet OstDepartment of Radiation Oncology, Iridium Netwerk, Wilrijk (Antwerp), Belgium; Department of Human Structure and Repair, Ghent University, Ghent, Belgium.
Joe M O'SullivanPatrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, Northern Ireland; Northern Ireland Cancer Centre, Belfast City Hospital, Belfast, Northern Ireland.
Anwar R PadhaniMount Vernon Cancer Centre and Institute of Cancer Research, London, UK.
Christopher ParkerRoyal Marsden Hospital and Institute of Cancer Research, Sutton, UK.
Darren M C PoonComprehensive Oncology Centre, Hong Kong Sanatorium & Hospital, The Chinese University of Hong Kong, Hong Kong.
Colin C PritchardDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
Danny M RabahThe Cancer Research Chair, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Dana RathkopfGenitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Robert E ReiterUniversity of California Los Angeles, Los Angeles, CA, USA.
Mark RubinBern Center for Precision Medicine, Bern, Switzerland; Department for Biomedical Research, University of Bern, Bern, Switzerland.
Charles J RyanMasonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Fred SaadCentre Hospitalier de Université de Montréal, Montreal, Canada.
Juan Pablo SadeInstituto Alexander Fleming, Buenos Aires, Argentina.
Oliver SartorTulane Cancer Center, New Orleans, LA, USA.
Howard I ScherGenitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Neal ShoreCarolina Urologic Research Center, Myrtle Beach, SC, USA.
Iwona SkonecznaRafal Masztak Grochowski Hospital in Warsaw, Warsaw, Poland; Maria Sklodowska Curie National Research Institute of Oncology, Warsaw, Poland.
Eric SmallUCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Matthew SmithMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Howard SouleProstate Cancer Foundation, Santa Monica, CA, USA.
Daniel SprattUniversity Hospitals Seidman Cancer Center, Cleveland, OH, USA.
Cora N SternbergEnglander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA; Division of Hematology and Oncology, Meyer Cancer Center, New York Presbyterian Hospital, New York, NY, USA.
Hiroyoshi SuzukiToho University Sakura Medical Center, Chiba, Japan.
Christopher SweeneyDepartment of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Matthew SydesMRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
Mary-Ellen TaplinDepartment of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Derya TilkiMartini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, Koc University Hospital, Istanbul, Turkey.
Bertrand TombalCliniques Universitaires Saint Luc, Brussels, Belgium.
Levent TürkeriDepartment of Urology, M.A. Aydınlar Acıbadem University, Altunizade Hospital, Istanbul, Turkey.
Hiroji UemuraYokohama City University Medical Center, Yokohama, Japan.
Hirotsugu UemuraDepartment of Urology, Kindai University Faculty of Medicine, Osaka, Japan.
Inge van OortRadboud University Medical Center, Nijmegen, The Netherlands.
Kosj YamoahDepartment of Radiation Oncology & Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, Tampa, FL, USA.
Dingwei YeDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Almudena ZapateroDepartment of Radiation Oncology, Hospital Universitario de La Princesa, Health Research Institute, Madrid, Spain.
Silke GillessenOncology Institute of Southern Switzerland, Bellinzona, Switzerland; Universita della Svizzera Italiana, Lugano, Switzerland; Cantonal Hospital, St. Gallen, Switzerland; University of Bern, Bern, Switzerland; Division of Cancer Science, University of Manchester, Manchester, UK.
Aurelius OmlinUniversity of Bern, Bern, Switzerland; Department of Medical Oncology and Haematology, Cantonal Hospital, St. Gallen, Switzerland.
Institute of Cancer Research · GBDana-Farber Cancer Institute · USMemorial Sloan Kettering Cancer Center · USUniversity of British Columbia · CADuke University · USMassachusetts General Hospital · USYokohama City University · JPAcıbadem University · TRAmerican University of Beirut Medical Center · LBCarolina Urologic Research Center · USCentre Hospitalier de l’Université de Montréal · CAChinese University of Hong Kong · HKCliniques Universitaires Saint-Luc · BEDana-Farber Brigham Cancer Center · USDuke Cancer InstituteEastern Health · AUFudan University Shanghai Cancer Center · CNHospital Universitario de La Princesa · ESHouston Methodist · USInnlandet Hospital Trust · NO
Funding
Medical Research Council MC_UU_00004/02Medical Research Council MC_UU_00004/08Medical Research Council MC_UU_12023/28
Abstract
Patients with advanced prostate cancer (APC) may be at greater risk for severe illness, hospitalisation, or death from coronavirus disease 2019 (COVID-19) due to male gender, older age, potential immunosuppressive treatments, or comorbidities. Thus, the optimal management of APC patients during the COVID-19 pandemic is complex. In October 2021, during the Advanced Prostate Cancer Consensus Conference (APCCC) 2021, the 73 voting members of the panel members discussed and voted on 13 questions on this topic that could help clinicians make treatment choices during the pandemic. There was a consensus for full COVID-19 vaccination and booster injection in APC patients. Furthermore, the voting results indicate that the expert's treatment recommendations are influenced by the vaccination status: the COVID-19 pandemic altered management of APC patients for 70% of the panellists before the vaccination was available but only for 25% of panellists for fully vaccinated patients. Most experts (71%) were less likely to use docetaxel and abiraterone in unvaccinated patients with metastatic hormone-sensitive prostate cancer. For fully vaccinated patients with high-risk localised prostate cancer, there was a consensus (77%) to follow the usual treatment schedule, whereas in unvaccinated patients, 55% of the panel members voted for deferring radiation therapy. Finally, there was a strong consensus for the use of telemedicine for monitoring APC patients. PATIENT SUMMARY: In the Advanced Prostate Cancer Consensus Conference 2021, the panellists reached a consensus regarding the recommendation of the COVID-19 vaccine in prostate cancer patients and use of telemedicine for monitoring these patients.
Indexed as
COVID-19Prostatic NeoplasmsAndrogen AntagonistsCOVID-19 VaccinesHumansMalePandemicsAndrogen AntagonistsCOVID-19 VaccinesCOVID-19 boost injectionCOVID-19 pandemicCOVID-19 vaccineProstate cancerProstate cancer managementTelemedicine
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.